GleamWall
中文EN

DARE Dare Bioscience, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1401914 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2,570.3%
TTM net income YoY39.4%
TTM EPS YoY66.7%
Revenue 3-yr CAGR12.2%
Net income 3-yr CAGR—

Margins

Gross margin26.4%
Operating margin-746.1%
Net margin-749.8%
FCF margin-1,279.2%
EBITDA margin-592.2%

Returns

ROE-407.1%
ROA-40.0%
ROIC (approx.)—
Asset turnover0.05x

Leverage & solvency

Liabilities / assets89.4%
Debt / equity0.00x
Current ratio1.23x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.66x
Accruals ratio26.4%
Payout ratio—
Capex / revenue34.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$47,628$187,546$152,455$1.02M$2,262-$21,172$25,427-$63,647
Cost of revenue$180,479$319,889$242,325$295,799$0$0$0—
Gross profit-$132,851-$132,343-$89,870$727,877$2,262-$21,172$25,427—
R&D expense$318,906$241,966$660,462$622,041$1.18M$1.43M$2.30M$3.34M
SG&A expense$2.64M$2.59M$2.25M$1.58M$2.50M$2.38M$2.31M$2.00M
Operating income-$3.09M-$2.97M-$3.00M-$1.47M-$3.67M-$3.83M-$4.58M-$5.39M
Net income-$3.16M-$2.98M-$3.00M-$1.44M-$3.56M-$4.02M-$4.38M-$5.51M
EBITDA-$2.58M-$2.40M-$2.44M-$936,873-$3.19M-$3.37M-$4.41M-$5.38M
EPS (basic)-0.18-0.20-0.21—-0.28-0.45-0.50—
EPS (diluted)-0.18-0.20-0.21—-0.28-0.45-0.50—
Weighted avg. shares (diluted)17.42M14.89M14.52M—12.76M8.87M8.76M—
Balance sheet
Cash & equivalents$11.53M$12.62M$18.52M$24.71M$23.08M$5.04M$10.33M$16.00M
Current assets$16.92M$16.69M$21.66M$27.06M$25.00M$6.60M$11.82M$18.45M
PP&E, net$1.51M$1.42M$1.45M$1.56M$1.66M$1.65M$1.48M$1.34M
Total assets$22.10M$22.37M$27.83M$32.47M$30.75M$12.98M$18.62M$22.10M
Current liabilities$13.71M$16.92M$21.12M$23.69M$21.22M$19.22M$21.19M$21.61M
Short-term debt————$10,542$187,966$91,907$4,054
Total liabilities$19.76M$22.93M$27.09M$29.63M$27.89M$25.71M$28.18M$28.11M
Shareholders' equity$2.34M-$560,100$734,451$2.84M$2.86M-$12.73M-$9.56M-$6.01M
Shares outstanding19.67M15.17M14.56M14.50M13.93M9.03M8.85M8.70M
Cash flow statement
Operating cash flow-$6.85M-$6.78M-$5.52M$1.58M-$578,008-$5.42M-$5.47M$5.31M
Capital expenditure$201,928$80,586$0$206,641$174,702-$153,396$157,331$562,849
Free cash flow-$7.05M-$6.86M-$5.52M$1.37M-$752,710-$5.26M-$5.63M$4.74M
Investing cash flow-$201,928-$80,586$0-$206,641-$174,702$153,396-$157,331-$562,849
Financing cash flow$5.96M$951,217-$715,470$424,129$18.65M-$43,794$246,577-$132,012
Depreciation & amortization$511,013$572,143$554,643$534,395$481,906$454,165$175,642$6,368
Stock-based compensation$400,000$286,602$455,064$357,160$400,000$359,018$377,357$489,260

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.